Two years ago, a study known as the JUPITER trial suggested the cholesterol-lowering statin drug might prevent heart-related death in many more people than just those with high cholesterol.
Now, however, researchers say that the JUPITER results are flawed -- and that they do not support the benefits initially reported. Not only is there no "striking decrease in coronary heart disease complications", but a new report has also called into question drug companies' involvement in such trials.
ABC News reports:
“... major discrepancies exists between the significant reductions in nonfatal stroke and heart attacks reported in the JUPITER trial and what has been found in other research ... ‘The JUPITER data set appears biased,’ [the researchers] wrote in conclusion.”